Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relmada Therapeutics Inc
(NQ:
RLMD
)
2.800
+0.050 (+1.82%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relmada Therapeutics Inc
< Previous
1
2
3
4
Next >
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
May 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
May 14, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Relmada Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Investor Alert: Investigation Concerning Potential Securities Laws Violations
May 11, 2023
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares over potential securities laws violations by Relmada...
Via
SBWire
Earnings Preview For Relmada Therapeutics
May 10, 2023
Via
Benzinga
Preview: Relmada Therapeutics's Earnings
March 22, 2023
Via
Benzinga
Relmada Shares Nosedive As Another Depression Trial Goes Up In Smoke
December 08, 2022
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation
May 11, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Earnings Scheduled For May 11, 2023
May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...
Via
Benzinga
RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm
May 09, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
May 01, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 27, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 26, 2023
From
The Schall Law Firm
Via
Business Wire
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 17, 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major...
Via
Benzinga
Looking Into Relmada Therapeutics's Recent Short Interest
January 03, 2023
Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 13.6% since its last report. The company recently reported that it has 1.72 million shares sold short, which is 5.78% of all...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 29, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 28, 2022
Via
Benzinga
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying
December 13, 2022
The Dow Jones closed higher by over 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 12, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 09, 2022
Via
Benzinga
Looking Into Relmada Therapeutics's Recent Short Interest
December 09, 2022
Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 8.99% since its last report. The company recently reported that it has 2.77 million shares sold short, which is 9.31% of all...
Via
Benzinga
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
December 08, 2022
U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 08, 2022
Via
Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
December 08, 2022
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Via
Benzinga
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
December 08, 2022
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.
Via
Benzinga
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
December 08, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining over 150 points on Thursday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 08, 2022
During Thursday's trading, 138 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 08, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 02, 2022
On Friday, 72 companies hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.